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Aims The chemokine receptor CCR5 and its inflammatory ligands have been linked to atherosclerosis, an accelerated form of
which occurs in saphenous vein graft disease. We investigated the function of vascular smooth muscle CCR5 in human
coronary artery and saphenous vein, vascular tissues susceptible to atherosclerosis, and vasospasm.
Methods
and results
CCR5 ligands were vasoconstrictors in saphenous vein and coronary artery. In vein, constrictor responses to CCL4 were
completely blocked by CCR5 antagonists, including maraviroc. CCR5 antagonists prevented the development of a neoin-
tima after 14 days in cultured saphenous vein. CCR5 and its ligands were expressed in normal and diseased coronary
artery and saphenous vein and localized to medial and intimal smooth muscle, endothelial, and inflammatory cells.
[125I]-CCL4 bound to venous smooth muscle with KD ¼ 1.15+0.26 nmol/L and density of 22+ 9 fmol mg21 protein.
Conclusions Our data support a potential role for CCR5 in vasoconstriction and neointimal formation in vitro and imply that CCR5
chemokines may contribute to vascular remodelling and augmented vascular tone in human coronary artery and vein
graft disease. The repurposing of maraviroc for the treatment of cardiovascular disease warrants further investigation.
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1. Introduction
The G-protein-coupled receptor, CCR5,1– 3 is activated by the inflam-
matory chemokines CCL3, CCL4, and CCL5, but only CCL4 exhibits se-
lectivity for CCR5 over other CC chemokine receptors.4 CCR5 is a
major co-receptor for the HIV-1 virus;5,6 however, in humans, a 32-bp
deletion results in a non-functional receptor protein that confers resist-
ance to HIV-1 infection.7,8 This observation gave impetus to the devel-
opment of small molecular weight antagonists and led to the approval
of maraviroc,9 the first of a new class of virus entry inhibitors, for use
in drug-resistant CCR5-tropic HIV-1 infection in 2007.
As patient life-expectancy increases, HIV-infected individuals are at
increased risk of cardiovascular events10,11 and poorer long-term out-
comes following coronary artery bypass grafting.10 This may be a
direct effect of HIV infection or the actions of some anti-viral protease
inhibitors.12 However, CCR5 and its ligands have been increasingly
linked to human atherosclerosis through studies on plasma chemokine
levels13,14 and genetic polymorphisms,15 with individual homozygous
for the delta-32 mutation exhibiting an inverse association with early
onset of coronary artery disease.16 Hypertension is a major risk for car-
diovascular disease, and while a direct correlation between blood pres-
sure and CCR5 genotype is debatable,17,18 prolonged treatment with
antiviral therapy is related to increased systolic blood pressure19,20
and pulmonary hypertension associated with vascular remodelling is
increased in HIV-positive individuals.21,22
We were particularly interested in the dose-limiting postural hypo-
tension reported for maraviroc23 that suggested to us a potential vaso-
dilator action of this drug via blockade of endogenous CCR5 tone.
Maraviroc is a highly selective CCR5 antagonist9 and therefore, we
hypothesized that CCR5 receptors localized to vascular smooth
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muscle cells contribute to increased vascular tone that may be of rele-
vance in coronary atherosclerosis in which expression of CCR5
ligands is increased. Additionally, we wished to determine whether
the CCR5 receptor contributed to intimal hyperplasia in vein graft
disease leading to graft failure that is exacerbated in individuals positive
for HIV-1.
We now report for the first time that smooth muscle CCR5 mediates
vasoconstriction in isolated saphenous vein and coronary artery in re-
sponse to CCL4 and CCL5 that can be abolished by CCR5 antagonists,
including maraviroc. We also find that neointimal development was
completely inhibited by CCR5 antagonists in a human saphenous vein
model of accelerated intimal hyperplasia. These data suggest that, in add-
ition to roles proposed for CCR5 in endothelial dysfunction and athero-
sclerosis, increased levels of CCR5 chemokines in disease may
contribute to vascular remodelling and augmented vascular tone or
acute vasospasm in human coronary artery and vein graft disease.
2. Methods
An expanded method section is available in Supplementary material online.
2.1 Tissue samples
Human tissues were obtained with informed consent from the Papworth
Hospital Research Tissue Bank (REC reference 08/H0304/56) and experi-
ments carried out with local ethical approval (REC 05/Q0104/142). Saphe-
nous vein and mammary artery were from 104 patients receiving coronary
artery bypass grafts. Other cardiovascular tissues were from 79 patients
undergoing cardiac or lung transplantation or nephrectomy. The study con-
formed to the principles outlined in the Declaration of Helsinki.
2.2 Human in vitro pharmacology
Endothelium-denuded saphenous vein and coronary artery were set up for
isometric force recordings, as described.24 Cumulative concentration re-
sponse curves were constructed to CCL4, CCL5 (0.1 pmol/L–
110 nmol/L), angiotensin-II (10 pmol/L–100 nmol/L), endothelin-1 (ET-1,
0.1–300 nmol/L), and phenylephrine (1 nmol/L–100 mmol/L). It should be
noted that a limitation of these experiments was that the maximum possible
concentration achievable in the organ bath for CCL4 and CCL5 was
110 nmol/L. In the vein, CCL4 responses were determined using +300
nmol/L of maraviroc to verify involvement of CCR5 and confirmed using 10
and 100 nmol/L of the chemically distinct CCR5 antagonist PF-232796.25
For dilator studies, the vein was pre-constricted with 10 nmol/L of ET-1 and
CCL4 (10 pmol/L–100 nmol/L) was added cumulatively. Data were analysed
using a four parameter logistic equation (GraphPad Prism 5) to give values of
pD2 (2log10 of the concentration that produces 50% of the fitted maximum
response) and maximum response (EMAX). Wire myography was performed
using the aorta from C57Bl/6 mice to determine whether CCL4 contracted a
blood vessel susceptible to atherosclerosis in another species.
2.3 Human saphenous vein organ culture
Saphenous vein organ culture was performed as described.26– 28 Using con-
secutive vein segments (1 cm), one segment (Day0 control) was immediate-
ly formalin-fixed and remaining segments cultured with +1 mmol/L of
maraviroc, PF-232796, or vehicle (0.1% dimethyl sulfoxide) for 14 days. Con-
ditioned culture medium was frozen (2708C) until required. Formalin-fixed
transverse segments were stained with haematoxylin and eosin, Alcian blue,
Miller’s elastin, and van Gieson’s stains28 to determine the cell number and
neointimal area, expressed as a percentage of total intimal + medial area.
2.4 Chemokine multiplex immunoassay
A custom 4-plex immunoassay for CCL2, CCL3, CCL4, and CCL5 was used
to determine chemokine concentrations in vein culture supernatant.
2.5 Reverse transcription polymerase chain
reaction assays
RNA was extracted and reverse transcribed from human tissues. PCR was
carried out using primers specific for Gsa, CCR5,29 CCL3, CCL4, and CCL5.
2.6 Quantitative reverse transcription
polymerase chain reaction
Total RNAwas extracted and expression of CCR5, CCL3, CCL4, CCL5, and
GAPDH determined using cDNA-specific TaqMan Gene Expression Inven-
toried Assays. Gene expression was quantified using the comparative
(DDCT) method. All samples were screened for Gsa to confirm cDNA in-
tegrity and the lack of gDNA contamination.
2.7 Western blot
Western blotting was performed on protein lysates of saphenous vein with
rabbit anti-CCR5.
2.8 Immunohistochemistry
Immunohistochemistry was performed as described.30 Sections of saphe-
nous vein and vein graft were used for additional colorimetric histology. Cul-
tured vein sections were processed for the analysis of proliferation
(phosphorylated-histone H3 and Ki67) and apoptotic (cleaved caspase-3)
markers, in addition to TUNEL staining.
2.9 Dual labelled fluorescent confocal
microscopy
Sections of human frozen tissues were processed30 and stained with rabbit
anti-human CCR5, CCL3, CCL4, or CCL5 and markers; mouse anti-human
von Willebrand factor (vWF), smooth muscle a-actin (SMaA), CD68 to
identify macrophages, or CD3 to detect T-lymphocytes. Secondary anti-
bodies Alexa Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor
568-conjugated goat anti-mouse IgG were incubated for 1 h (228C). Slides
were mounted in ProLong Gold reagent, cured for 24 h, and viewed with
a confocal laser scanning microscope.
2.10 Tissue profiling using receptor
autoradiography
Receptor autoradiography31 was carried out using cryostat-cut sections of
human tissues and 0.1 nmol/L of [125I]-CCL4. Non-specific binding (NSB)
was defined using 100 nmol/L of CCL4.
2.11 Saturation and competition analysis
Saphenous vein (10 mm sections) was incubated for 2 h (228C) with
[125I]-CCL4 (2 pmol/L–2 nmol/L). NSB was defined by 1 mmol/L of CCL4.
In competition experiments, sections were incubated with 0.1 nmol/L of
[125I]-CCL4 and increasing concentrations of CCL4 or maraviroc (10 pmol/
L–2 umol/L). Sections were opposed, with standards, for 5 days to radiation-
sensitive film. Autoradiograms were analysed using computer-assisted densi-
tometry.31
2.12 Statistical analysis
N-values are the number of patients from which tissues were obtained. For
in vitro pharmacology data, EMAX and pD2 values were compared using
Student’s two-tailed t-test or one-way analysis of variance, followed by
Bonferroni’s multiple comparison tests. Receptor autoradiography was
analysed by one-way analysis of variance followed by Tukey’s or Bonferroni’s
multiple comparison tests. Where there was evidence of non-normality
non-parametric statistical analysis was performed with data expressed as
median (range). For quantitative reverse transcription polymerase chain re-
action, analysis of different genes within the same tissues was done by the
Friedman test followed by Dunn’s multiple comparison test. Comparison
between different tissues used the Kruskall–Wallis test followed by the
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Mann–WhitneyU-test with Bonferroni correction applied. For vein culture,
comparisons between paired datawere by the Wilcoxon signed-rank test or
the Friedman test for related samples followed by Dunn’s multiple compari-
son test. A P-value of ,0.05 was considered significant.
3. Results
3.1 CCR5 mediates constriction of human
saphenous vein and coronary artery
In pre-constricted saphenous vein, CCL4 had no direct dilator actions
(n ¼ 4) (seeSupplementarymaterialonline,Figure S1A).CCL4contracted
tissue from 13 of 19 veins tested. In seven of these responsive veins, a
maximum response was achieved at 110 nmol/L CCL4; however, for
the remaining tissues, a maximum response was not obtained, although
thereweresufficientdata foracurvefit toderivebothmaximumresponse
and EC50. Therefore, our values of potency and maximum response for
CCL4 in saphenous vein should be regarded as estimates. With this
caveat, the order of potency of the four agonists tested was angiotensin-II
(pD2 ¼ 8.80+0.23, n ¼ 10). ET-1 (pD2 ¼ 7.92+0.17, n ¼ 6) ≥
CCL4 (pD2 ¼ 7.67+0.19, n ¼ 13). phenylephrine (pD2 ¼ 6.31+
0.21, n ¼ 10). Comparing the maximum constrictor responses of the
four agonists, the order of efficacy was ET-1 (EMAX ¼ 98+7% KCl).
phenylephrine (EMAX ¼ 65+8% KCl). angiotensin-II (EMAX¼ 40+
3% KCl) ¼ CCL4 (EMAX ¼ 39+8% KCl) (Figure 1A). CCL5 contracted
saphenous vein with pD2 comparable with CCL4 (CCL5 pD2 ¼ 7.56+
0.37, EMAX ¼ 17+8% KCl, n ¼ 5).
In coronary artery vasoconstrictor responses to CCL4 were obtained
in all the five arteries tested and a maximum response was achieved to
CCL4 for 4/5 of these. The orderof agonist potency was as for saphenous
vein; angiotensin-II (pD2 ¼ 9.20+ 0.41, n ¼ 6). ET-1 (pD2 ¼ 8.28+
0.18, n ¼ 6) ≥ CCL4 (pD2 ¼ 8.07+0.42, n ¼ 5). phenylephrine
(pD2 7.43+0.14, n ¼ 9/16) (Figure 1B). The maximum responses to
CCL4 (EMAX 26+7% KCl); angiotensin-II (EMAX 27+9% KCl), and
phenylephrine (EMAX 33+8%KCl)werecomparable, but allwere signifi-
cantly lower than that to ET-1 (106+13% KCl) (P, 0.05). In the pres-
ence of 300 nmol/L maraviroc, CCL4 constriction was abolished
(Figure 1C). PF-232796 (10 nmol/L) produced a rightward shift of the
CCL4 concentration response curve with abolition at 100 nmol/L
PF-232796 (Figure 1D). Maraviroc (300 nmol/L) had no effect on
responses to phenylephrine or ET-1 in saphenous vein (not shown).
CCL4 contracted mouse aorta with pD2 ¼ 9.79+0.23 (n ¼ 10) (see
Supplementary material online, Figure S1C).
3.2 CCR5 antagonists inhibit intimal
thickening in a model of vein graft disease
By Day 14, vein segments had developed a neointima containing
smooth muscle cells and extracellular matrix (Figure 2A and B, and see
Supplementary material online, Figure S2A, B, E, and G). Medial and neoin-
timal layers expressed CCR5 mRNA (n ¼ 5) (see Supplementarymaterial
online, Figure S2J) and protein (n ¼ 4 pooled, Figure 2C–E) localized to
smooth muscle cells (see Supplementary material online, Figure S2K).
CCL3,CCL4, andCCL5mRNA(n ¼ 5,Figure2F) andprotein (seeSupple-
mentary material online, Figure S3A–C) were also identified, localized to
neointimal smooth muscle cells (see Supplementary material online,
Figure S4), and all the three ligands were detected in culture medium
(n ¼ 7–8, Figure 2G). Total CCL2 release over the culture period, mea-
sured for comparison, was significantly greater than CCL3 or CCL5
release (n ¼ 9, P, 0.01 and ,0.001) and CCL4 release was significantly
greater than CCL5 (n ¼ 9, P, 0.05, see Supplementary material online,
Figure S3D).
In vein segments, co-culture with maraviroc (Figure 2H) and
PF-232796 (Figure 2I) inhibited the development of intimal thickening
(P, 0.05). Little staining for cleaved caspase-3 was observed in veins
cultured without or with maraviroc or PF-232796 (see Supplementary
material online, Figure S5A–F). There was no difference in cell density
in segments cultured with vehicle or CCR5 antagonists (see Supplemen-
tary material online, Figure S5G and H). A significant increase in CCL5
release was seen with maraviroc (P, 0.05), although no difference
was observed for CCL3, CCL4, or CCL2 (n ¼ 7). Co-culture with
PF-232796 did not lead to significant alterations in chemokine release
(n ¼ 6–7) (see Supplementary material online, Figure S6). There was
no evidence for alterations in the extent of apoptosis or proliferation
in veins cultured with antagonists compared with vehicle (see Supple-
mentary material online, Figures S7–9).
3.3 CCR5 identified in human
cardiovascular tissues
Full-length CCR5 transcripts were identified in cardiomyocytes, media
of aorta, pulmonary and coronary artery, and saphenous vein
(Figure 3A). Infrequently, a smaller band was identified consistent with
individuals being homozygous or heterozygous for the CCR5 delta
32-deletion polymorphism (e.g. Figure 3A, lane 4). Western blotting con-
firmed a single band at 75 kDa in the saphenous vein (Figure 3B). Spe-
cific CCR5 immunoreactivity was detected in the normal saphenous
vein and coronary artery (Figure 3C and D). Using specific markers,
CCR5 immunoreactivity co-localized to endothelial and medial
smooth muscle cells in the saphenous vein and coronary artery (see Sup-
plementary material online, Figure S10) and to smooth muscle of small
Figure 1 Vasoconstrictor responses to CCL4 (filled circle),
angiotensin-II (Ang-II, filled square), phenylephrine (PE, filled triangle),
and endothelin-1 (ET-1, filled diamond) in human endothelium-
denuded (A) saphenous vein (n ¼ 6–13) and (B) coronary artery
(n ¼ 4–9). Antagonism of (C) CCL4 (filled circle) by 300 nmol/L mar-
aviroc (filled square) (n ¼ 4) and by (D) 10 nmol/L (filled square) and
100 nmol/L (filled triangle) PF-232796 (n ¼ 4) in saphenous vein.
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intramyocardial vessels and surrounding cardiomyocytes in the heart
(Figure 3G).
By autoradiography, we detected a significant difference in specific
binding of [125I]-CCL4 across a panel of human tissues (P, 0.001,
one-way ANOVA; Figure 3I and J, and see Supplementary material
online, Figure S11A). Compared with the highest density in coronary
artery media, levels of receptor expression were not different in the
media of other arteries, heart, or kidney medulla, but were significantly
lower (Tukey’s multiple comparison test, P, 0.05) in saphenous
vein, kidney cortex, and lung. Binding of [125I]-CCL4 was reduced
by maraviroc, consistent with it acting as an allosteric modulator (see
Supplementary material online, Figure S11C). Saturation analysis con-
firmed that [125I]-CCL4 bound to media of saphenous vein with a
single nanomolar affinity (KD ¼ 1.15+0.26 nmol/L, n ¼ 3). The Hill
slope was 1.14+0.06 with a receptor density of 22+9 fmol mg21
protein.
Figure 2 Contribution of CCR5 to intimal hyperplasia in cultured saphenous vein. Cross-section through saphenous vein segment after (A) 0 and (B) 14
days in culture showing the development of a neointima (arrow heads) by Day 14. (C) CCR5 protein detected by western blotting (n ¼ 4, pooled). (D)
CCR5 immunoreactivity localized to medial and neointimal layers of cultured vein with staining absent (E) when the primary antibody was omitted. (F)
CCL3, CCL4, and CCL5 mRNA (n ¼ 5) weredetected in culturedvein and in culturemedium (G) during culture (n ¼ 7–8). Co-culturewith CCR5 antago-
nists (H ) maraviroc (MVC, n ¼ 10) and (I ) PF-232796 (PF, n ¼ 9) inhibited the development of intimal thickening (P, 0.05, Friedman test followed by
Dunn’s multiple comparison test). Values are median (range).
J.J. Maguire et al.4
 at U
niversity of Cam
bridge on A
ugust 18, 2014
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
Figure 3 CCR5 mRNA and protein expression in human cardiovascular tissues. (A) Transcripts for CCR5 (179 bp) in media of coronary artery (CA),
aorta (Ao), pulmonary artery (PA), cardiomyocytes (cm), and saphenous vein (SV). Transcripts forD32 polymorphic (147 bp)CCR5 in PA(lane 4). Ladders
are 100 bp. (B) Western blot confirmed a single band at 75 kDa in saphenous vein (n ¼ 9, three pooled samples). CCR5 immunoreactivity localized to
media (M) and endothelium (EC) of normal (C) saphenous vein and (D) coronary artery with staining abolished on omission of the primary antibody (E and
F). CCR5wasco-localized to the smooth muscle of (G) small intramyocardial coronaryvesselswith SMaAand waspresenton surrounding cardiomyocytes
with (H ) staining abolished when primary antibodies were omitted. (I) Relative density of [125I]-CCL4 binding in human tissues (n ¼ 3–9; * significantly
different from coronary media; † significantly different from mammary artery; ‡ significantly different from radial artery; P, 0.05). (J ) Representative auto-
radiograms showing total and NSB in sections of coronary artery (CA), saphenous vein (SV), mammary artery (MA), and radial artery (RA), scale
bar ¼ 2 mm.
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3.4 CCR5 ligands are expressed in human
cardiovascular tissues
CCL3, CCL4, and CCL5 mRNAwere detected in aorta, pulmonary, cor-
onary and mammary artery, saphenous vein, and cardiomyocytes
(Figure 4A). Immunoreactivity to all the three ligands was detected in
the endothelium and media of epicardial and intramyocardial coronary
artery, saphenous vein, and in cardiomyocytes (Figure 4B, and see Sup-
plementary material online, Figure S12).
3.5 CCR5 and ligand expression in coronary
atherosclerosis, saphenous vein graft, and
heart failure
In atheroscleroticplaqueofdiseasedcoronaryartery (Figure5A) and thick-
ened intima of failed saphenous vein graft (Figure 5B), CCR5 immunoreac-
tivity was expressed in smooth muscle cells, macrophages, and to lesser
extent CD3-positive cells. Compared with saphenous vein and donor
myocardium, there was no significant alteration in CCR5 mRNA in saphe-
nous vein graft or in hearts from patients transplanted for dilated cardio-
myopathy (DCM) or ischaemic heart disease (IHD), the two most
common diagnoses for cardiac transplantation32 (Figure 5C and D).
There was no difference in receptor density between coronary artery
media and intimal layers and media of saphenous vein and vein graft
(P. 0.05, one-way analysis of variance followed by Bonferroni’s multiple
comparison test; Figure 3I). A similar cellular localization was obtained for
CCL3,CCL4, andCCL5as for CCR5 in coronaryartery plaqueand intima
of failed vein graft (Figure5E, and see Supplementary material online, Figure
S13) and whereas levels of mRNA encoding CCR5 ligands were not dif-
ferent in normal and diseased saphenous vein (Figure 5F) comparison in
donor compared with DCM or IHD ventricle showed highest expression
of ligands in the IHD group, with CCL5 significantly increased compared
with donors (Figure 5G, P, 0.05).
4. Discussion
We have examined whether CCR5 ligands have direct vasoactive
actions on human blood vessels to understand the mechanism under-
lying the postural hypotension reported for maraviroc in healthy volun-
teers.23 We now report for the first time that, at least in vitro, the CCR5
receptor on human vascular smooth muscle mediates vasoconstriction
in response to nanomolar concentrations of CCL4 and CCL5 and con-
tributes to neointimal hyperplasia in a model of human vein graft disease.
The involvement of CCR5 in these responses was confirmed by their
blockade by maraviroc.
We next carried out a detailed analysis of the receptor pharmacology
and expression pattern of CCR5 and its ligands in human cardiovascular
tissues. In saphenous vein, CCR5 identified a single nanomolar affinity in
agreement with that reported for human CCR5 expressed in HEK 293
cells.2 We obtained a CCR5 binding density of 20 fmol mg21 protein,
which is comparable with other vasoconstrictor peptide receptors
including the endothelin ETA receptor (190+23 fmol mg
21)33 and the
thromboxane TP receptor (6+2 fmol mg21).34 Binding of [125I]-CCL4
was inhibited by the CCR5 antagonists, confirming the interaction of
ligand with receptor rather than tethering of CCL4 to cell surface glyco-
saminoglycans. Using receptor autoradiography and immunocytochem-
istry, we have shown that CCR5 is expressed on vascular smooth
muscle in a range of human arteries, including coronary artery. In contrast
to previous reports,35 we have demonstrated CCR5 mRNA and protein
on venous smooth muscle consistent with our receptor binding and
observation that CCL4 and CCL5 are vasoconstrictors in the human sa-
phenous vein. As far as we are aware this is the first report of vasoactivity
of CC chemokines, although the CXCR4 ligand SDF-1a has been shown
to contracthumancoronary artery microvessels.36 Importantly, we found
that CCL4 was an equally effective constrictor of human epicardial
coronary arteries in vitro.
Figure 4 Expression of CCR5 ligands in human cardiovascular
tissues. (A) Transcripts for CCL3, CCL4, and CCL5 in myocytes,
aorta (Ao), pulmonary (PA), coronary (CA), and mammary (IMA)
artery and saphenous vein (SV). Ladders are 100 bp. (B) Expression
of CCL3 immunoreactivity (green) co-localized (orange/yellow in
overlay) with vWF and SMaA (red) in coronary artery, saphenous
vein and to a small intramyocardial vessel and surroundingmyocardium
in the left ventricle. CCR5 immunoreactivity was absent on omission of
primary antibody.
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Figure 5 CCR5 receptor protein expression in (A) coronary atherosclerotic plaque and (B) thickened intima of failed saphenous vein graft.
Co-localization (overlay: yellow/orange, arrow heads) of CCR5 immunoreactivity (green) with SMaA, CD68, and CD3-positive cells (red). Lack of fluor-
escence on omission of primary antibody shown for the vein graft. Scale bars: 30 mm. Relative levels of CCR5 mRNA in (C) saphenous vein (SV n ¼ 5) and
vein graft (SVG n ¼ 4) and (D) donor (n ¼ 5), DCM (n ¼ 6) and ischaemic (IHD n ¼ 5) myocardium. (E) Expressionof CCL3 in saphenous vein graft: CCL3
immunoreactivity (green) co-localized in overlay (orange/yellow) with vWF, SMaA, CD68, and rarely CD3-positive cells (red). (F) Expression of CCL3,
CCL4, and CCL5 mRNAwascomparable in graft (SVG, n ¼ 6) and normal vein (SV, n ¼ 6). (G) In the left ventricle, CCL5 mRNAwas significantly increased
in IHD compared with donor (*P, 0.05, n ¼ 6).
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A direct effect of CCR5 ligands on vascular smooth muscle has not
previously been studied to any extent, although the HIV-1 virus has re-
cently been shown to infect vascular smooth muscle cells resulting in
release of the pro-inflammatory chemokine CCL2.37 This action is de-
pendent on the expression of CD4 and a co-receptor such as CCR5. Ac-
tivation of smooth muscle CCR5 by viral gp120 is linked to the release of
tissue factor.38 Interestingly, CCL4 was reported to increase tissue
factor activity in human cultured vascular smooth muscle cells;39
however, the consequence of activation of smooth muscle CCR5 by en-
dogenous chemokine ligands has not been further investigated. One
reason for this may be that individuals homozygous for the CCR5
delta 32 polymorphism do not exhibit a significant cardiovascular
phenotype. Despite this, the mutation has been associated with
decreased cardiovascular risk40 and circulating levels of CCL5 are
increased in cardiovascular disease.41,42 In patients with unstable
angina,41 CCL5 is detectable in the nanomolar range, and in a study of
hypertensives, those individuals with the highest plasma levels of
CCL4 had a higher risk of stroke and cardiovascular events with the
authors concluding that CCL4 contributed to the development of ath-
erosclerosis.43 The plasma levels of CCL4 detected in these hyperten-
sives was 44–336 pg mL21 which based on the affinity for CCL4
determined in our radioligand binding assay would produce a level of
CCR5 receptoroccupancyof between84 and 97%. Our in vitrovasocon-
strictor data suggest that these levels of plasma CCL4, at least in hyper-
tensive patients, would occupy most of the available receptors with the
potential to contribute to increased vascular tone. Plasma levels of che-
mokine/cytokine biomarkers, including CCL4 and CCL5, are also signifi-
cantly increased in patients receiving coronary artery bypass grafts.44
Perioperative vein graft spasm is a serious complication contributing
to graft failure45 and postoperative spasm, though rare, can be fatal.46
If CCR5 ligands are present locally at sufficient concentrations, our
observations suggest that these mediators, acting through vascular
CCR5, may also contribute to graft spasm at the time of operation.
As reported by others,39,47 we observed that CCR5 and its ligands
were expressed in atherosclerotic coronary artery and failed saphenous
vein graft by intimal smooth muscle cells likely to be of a ‘synthetic’
phenotype,48 macrophages, and rarely by CD3+ T-cells. The presence
of both receptor and ligands in the intima provides evidence for para-
crine signalling during disease progression promoting neointimal thick-
ening. In particular, CCL5/CCR5 is considered crucial to monocyte
recruitment during the development of native vessel atheroscler-
osis.49,50 We observed expression of CCR5 by both contractile and pro-
liferative vascular smooth muscle cells, comparable with the constrictor
thromboxane,34 but this contrasts with our observation that receptors
forET-1aredownregulated in the intima ofdiseasedcoronaryarteryand
saphenous vein.51,52
Having identified the CCR5 system in saphenous vein and failed vein
graft, we next addressed the question of a functional role for CCR5 in
graft disease. There is increasing evidence from animal models53 that
chemokine receptors, including CCR5, contribute to intimal hyperpla-
sia; however, maraviroc has little if any affinity for rodent CCR5 and
therefore, we used a model of human intimal hyperplasia in which to in-
terrogate the consequence of CCR5 antagonism. This is a static organ
culture model, without flow conditions, that recapitulates some
aspects of the in vivo condition and therefore, caution is required when
interpreting the results. However, the advantage of this model is that
it utilizes a clinically relevant human tissue. Following saphenous vein
culture, development of a neointimal layer was evident, as previously
reported.26,27 Similar to native vein graft, we detected CCR5 and
ligands in cultured vein localized to intimal smooth muscle cells.
CCL3, CCL4, CCL5, and CCL2 were released during culture, with
intimal smooth muscle cells54,55 a likely source. Increased CCL5
release was observed on co-culture with maraviroc consistent with a
feedback cycle between CCL5 and CCR5.56 The detection of CCL2
release is supported by a previously reported association between
CCL2 expression and intimal thickening in rat vein graft.57 Importantly,
in this model, antagonism of CCR5 by two structurally distinct antago-
nists abolished the development of intimal thickening, confirming a
role for CCR5. This is unlikely to be due to toxicity as maraviroc was
non-toxic with respect to cell proliferation in culture,9 and we found
no evidence for increased cell death and no difference in cell density
between segments cultured with vehicle or CCR5 antagonists.
Finally, we detected expression of CCR5 in cardiomyocytes, but any
effect of CCR5 ligands on cardiac contractility remains to be investi-
gated. SDF-1 reportedly inhibited cardiac contractility in isolated
rodent myocytes and was blocked by the CXCR4-selective antagonist
AMD3100.58 Inhuman heart failure,we foundnochange in CCR5recep-
tor density but detected increased levels of CCR5 ligands in patients
transplanted for IHD, the relevance of which is to be determined.
In summary, we report that CCR5 is widely expressed by human car-
diovascular tissues and mediates potent vasoconstriction of human arter-
ies and veins by its ligands CCL4 and CCL5. This response can be
antagonized by maraviroc. We speculate that CCR5 antagonists, used
as virus entry inhibitors, may have additional benefits to slow progression
of virus- or drug- treatment-associated vascular complications in this
patient group. In addition, CCR5 and its ligands are present in human sa-
phenous vein and saphenous vein graft tissue, and antagonism of CCR5
inhibits the development of intimal thickening in vein in vitro. There are lim-
itations to our studies in that they report only on the vasoconstrictor and
proliferative potential of CCR5 ligands in human blood vessels in vitro.
Therefore, extrapolation to the in vivo clinical setting requires further in-
vestigation to confirm whether blocking chemokine receptors, such as
CCR5, may be a novel strategy for the treatment of vascular disease.
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